Molecular Formula | C8H5ClF3NO.ClH.H2O |
Molar Mass | 278.06 |
Melting Point | 156-158°C |
Boling Point | 282.3°C at 760 mmHg |
Flash Point | 124.5°C |
Vapor Presure | 0.00339mmHg at 25°C |
Storage Condition | Inert atmosphere,Room Temperature |
Physical and Chemical Properties | Appearance: light yellow powder |
Hazard Symbols | Xi - Irritant |
overview | efavirenz (Elavirenz), the chemical name is (4S) -6-chlorine -4-(cyclopropylacetylene)-4-(trifluoromethyl)-benzo -1,4-dihydrooxazole -2-one, developed by Merck Company of the United States, is a specific drug against HIV, it belongs to the category of non-nuclear reverse transcriptase inhibitors and is mainly used for human immune virus A (HIV type 1). It was approved for listing by the Food and Drug Administration (FDA) in February 1999 with a Sustiva trade name. |
properties | favirenz belongs to the category of non-nucleoside reverse transcriptase inhibitor (NNRTI-non-nucleoside reverse transcriptase inhibitor) Anti-retroviral (antiretrovirals) drugs, both nucleoside-based RTI and non-nucleoside-based RTI are intended to inhibit the same target, namely reverse transcriptase (reverse transcriptase enzyme). This enzyme is transcribed from RNA into DNA, and it is extremely important for virus reproduction. |
adverse reactions | side effects are often accompanied by the following psychopathological symptoms: insomnia, confusion, confusion, memory loss, emotional depression, etc. Rash, nausea, dizziness and headache may also occur. According to Weilun may cause defects in newborn babies, so it should not be used for women with pregnancy opportunities, the safety of use in infants has not yet been confirmed; the use of Eviron may also lead to a false positive urine test for marijuana substances. |